PMS34 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES

May 1, 2011, 00:00 AM
10.1016/j.jval.2011.02.719
https://www.valueinhealthjournal.com/article/S1098-3015(11)00858-8/fulltext
Section Title : Disease-Specific Studies
Section Order : 177
First Page : A129
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00858-8&doi=10.1016/j.jval.2011.02.719
HEOR Topics :
Tags :
Regions :